A Phase I-II, Randomized, Double-Blind, Study to Evaluate the Safety, Tolerability, and Immunogenicity of Different Formulations of V114 in Healthy Adults and Infants
A Phase I-II, Randomized, Double-Blind, Study to Evaluate the Safety, Tolerability, and Immunogenicity of Different Formulations of V114 in Healthy Adults and Infants
This study is designed to assess the effect of different dose levels of pneumococcal polysaccharide and adjuvant on the safety and immunogenicity of V114 in healthy adults and infants.
Inclusion Criteria:
Adult Cohort: 18 to 49 years and in good health
Infant Cohort: approximately 2 months (42 to 90 days) and in good health.
Exclusion Criteria:
Adult cohort: Prior administration of any pneumococcal vaccine